May 7, 2026
MedTech Breakthrough, an independent market intelligence organization that recognizes the most innovative companies, technologies and products in the global digital health and medical technology market, today announced that Evergen, a leading CDMO pushing the boundaries of innovation and tissueengineering to meet patient needs in regenerative medicine, has been selected as winner of the “Best Overall MedTech Company” award in the 10th annual MedTech Breakthrough Awards program.
Evergen’s agile, patient-first Contract Development and Manufacturing Organization (CDMO) partnership model and clinical expertise allow it to deliver the optimum biomaterial in the ideal form for each procedure, with comprehensive, end-to-end services. Evergen partners with Original Equipment Manufacturers (OEMs) to design, develop, andmanufacture customized biomaterial solutions for regenerative medicine that promote healing, accelerate recovery and help prevent complications to enhance patient lives.
Evergen focuses on specialized clinical areas, including plastic and reconstructive surgery, sports medicine and orthopedics, neuro/spine, and cardiac. By combining deep clinical and advanced biomaterials expertise, Evergen first collaborates with OEMs to understand patients' unique needs, clinical applications, and gaps in existing treatment options. The company then leverages its extensive portfolio of allograft and xenograft biomaterials to develop the best biomaterial in the ideal form for each procedure.
Complemented by a robust ISO 13485–compliant multi–site infrastructure, a rigorous quality management program and comprehensive capabilities, the company has the flexibility to tailor and scale end-to-end services for customers, from startups to global medical device leaders. With Evergen, customers can build scalable solutions by optimizing processes and advancing manufacturing capabilities.
“Our ability to work with multi-source biomaterials at scale while ensuring quality, reliability, and supply assurance is why we stand out and why OEMs can rely on us. Our customers consistently cite our team and collaborative culture as a defining strength, enabling faster innovation and more effective problem-solving,” said Olivier Visa, CEO of Evergen. “We’re grateful to MedTech Breakthrough for this acknowledgment. At our core, it is passion, agility, and an unwavering focus on improving patient outcomes that guide how we solve challenges for our partners and help them meet ambitious goals.”
Now celebrating its 10th anniversary, the MedTech Breakthrough Awards program has spent a decade recognizing the companies driving meaningful progress and improving patient care across the global health and medical technology industry. The program spans a wide range of categories – including Telehealth, Clinical Administration, Patient Engagement, Electronic Health Records (EHR), Virtual Care, Medical Devices and beyond – honoring the innovations reshaping how care is delivered worldwide.
This year's program drew a record-breaking number of nominations from leading companies and startups across more than 20 countries, reflecting the growing global impact and momentum of the digital healthcare industry.
“Evergen is redefining what it means to be a CDMO in regenerative medicine by leading with the patient. Traditional innovation approaches usually begin with biomaterials, Evergen goes beyond by first considering unmet clinical and patient needs. This makes turning concepts into practical solutions for regenerative medicine that meet functional, mechanical and regulatory standards for clinical use incredibly complex,” said Steve Johansson, managing director, MedTech Breakthrough. “Through ongoing investment in talent, operational excellence, and next-generation biomaterials, Evergen is shaping the future of regenerative medicine as a trusted, agile, and innovative partner.”
Additionally, Evergen participates in the Medical Device Discovery Appraisal Program (MDDAP), a voluntary program that helps medical device manufacturers better understand, measure, and improve their capabilities to deliver high-quality products.
